About: Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • To evaluate the efficancy and safety of dulanermin combined with paclitaxel and carboplatin and bevacizumab as first fine treatment for advanced or recurrent nonsmall cell lung cancer (NCLC). The study found that the addition of dulanermin to carboplatin and bevacizumab did not improve outcome in unselected patinets with previously untreated advanced or recurrent NSCLC
  • To evaluate the efficancy and safety of dulanermin combined with paclitaxel and carboplatin and bevacizumab as first fine treatment for advanced or recurrent nonsmall cell lung cancer (NCLC). The study found that the addition of dulanermin to carboplatin and bevacizumab did not improve outcome in unselected patinets with previously untreated advanced or recurrent NSCLC (en)
Title
  • Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
  • Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer (en)
skos:prefLabel
  • Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
  • Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer (en)
skos:notation
  • RIV/00064211:_____/11:#0000101!RIV12-MZ0-00064211
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • N, Z(MZ00000064211)
http://linked.open...iv/cisloPeriodika
  • 33
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 225681
http://linked.open...ai/riv/idVysledku
  • RIV/00064211:_____/11:#0000101
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • randomised phase II study; dulanermin; combination; paclitaxel; carboplatin; bevacizumab; advanced; non-small cell lung cancer (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [988823164A9A]
http://linked.open...i/riv/nazevZdroje
  • Journal of Clinical Oncology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 19
http://linked.open...iv/tvurceVysledku
  • Zatloukal, Petr
  • Pan, Y.
  • Albert, I.
  • Amler, L.
  • Ashkenazi, A.
  • Baker, N.
  • Blackhall, F.
  • Hei, Y. J.
  • Juhász, E.
  • Kozielski, J.
  • Márk, Z.
  • Pujol, J. L.
  • Smethurst, D.
  • Soria, JC
  • Stern, H.
  • Szima, B.
http://linked.open...n/vavai/riv/zamer
issn
  • 0732-183X
number of pages
http://bibframe.org/vocab/doi
  • 10.1200/JCO.2011.37.2623
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software